What is CVE-2023-38956?

CVE-2023-38956 is a high-severity vulnerability in Zkteco Bioaccess Ivs, classified under Path Traversal. CVSS score: 7.5/10. Published 2023-08-03.

How severe is CVE-2023-38956?

High severity. CVSS v3 base score is 7.5 out of 10.

Path Traversal in Zkteco Bioaccess Ivs

CVE-2023-38956

A path traversal vulnerability in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to read arbitrary files via supplying a crafted payload.

Vulnerability class: Path Traversal (Directory Traversal)

Published 2023-08-03 · last modified 2026-07-09.

CVSS v3 metric

CVSS v3 base score 7.5 (High). Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N.

EPSS exploit prediction

EPSS: 0.007 (52.3th percentile), scored 2026-09-29.

Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 52nd percentile — 52.3% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS over last 30 days · oldest: 0.007 · newest: 0.007 · change: +0.000

Affected products

Zkteco Bioaccess Ivs — versions 3.3.1

Weakness classification (CWE)

CWE-22 — Path Traversal

References

af854a3a-2127-422b-91ae-364da2661108 (Not Applicable)
claroty.com/team82/disclosure-dashboard/cve-2023-38956 (Third Party Advisory)

Frequently asked questions

What is CVE-2023-38956?: CVE-2023-38956 is a high-severity vulnerability in Zkteco Bioaccess Ivs, classified under Path Traversal. CVSS score: 7.5/10. Published 2023-08-03.
How severe is CVE-2023-38956?: High severity. CVSS v3 base score is 7.5 out of 10.